3 No-Brainer Medical Device Stocks to Buy Right Now
These companies have consistently delivered revenue and EPS gains.
Stay updated with breaking news from Abbott Navitor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
These companies have consistently delivered revenue and EPS gains.
Abbott (NYSE:ABT) announced today that studies support its next-generation Navitor TAVI system and its Amplatzer Amulet device.
Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant
Abbott (NYSE:ABT) announced today that it received FDA approval for its latest-generation transcatheter aortic valve implant (TAVI) system.
May 17, 2021 11:35am The Navitor artificial heart valve is implanted using Abbott’s CE-marked FlexNav delivery device and reduces the blood leaks that often occur after replacement. (Abbott) After Boston Scientific retired its entire line of Lotus Edge replacement heart valves late last year amid a flurry of issues with its delivery system, Abbott has stepped up to fill in the gap in the transcatheter aortic valve replacement market. Abbott’s Navitor TAVR system has received a CE mark, making it available in Europe to those with severe aortic stenosis and a high or extreme risk of...